TAE Life Sciences fetches $40 mln Series A in ARTIS Ventures-led round
TAE Life Sciences, a developer of treatments for difficult to treat cancers, has raised $40 million in Series A funding. ARTIS Ventures led the round.
12 March 2018•1 min read
TAE Life Sciences, a developer of treatments for difficult to treat cancers, has raised $40 million in Series A funding. ARTIS Ventures led the round.
